Trial Profile

Safety and Efficacy Study of Conbercept in Diabetic Macular Edema (DME) (Sailing)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 10 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Conbercept (Primary)
Indications Diabetic macular oedema
Focus Therapeutic Use
Acronyms Sailing
Sponsors Chengdu Kanghong Biological Science & Technology; Chengdu Kanghong Biotech

Most Recent Events

01 Oct 2022 2 years Results assessing efficacy and safety of intravitreal injections of conbercept versus laser photocoagulation ,published in the British Journal of Ophthalmology
08 Jun 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
22 Jul 2014 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com